EUVIMEDEUVIMED entdecken
Qualitative StudieOpen Access · CC BY-NC 4.0

Incorporating the Patient Voice into Attribute and Level Selection for a Preference Study: A Qualitative Study in Non-Muscle Invasive Bladder Cancer

Brad Mason, Anthony Eccleston, Lara Ayala-Nunes, Brett Hauber, Adam Gater, Joshua Coulter, Pam Hallworth, Allison Thompson, Bethany Bell, Jane Chang, Julia Brinkmann, Joseph C Cappelleri und 2 weitere

The Patient - Patient-Centered Outcomes Research · 2026

DOI: 10.1007/s40271-026-00804-7 ↗

Kurz gefasst

Qualitative Studie in der Zeitschrift The Patient - Patient-Centered Outcomes Research, 2026. Verfasst von Brad Mason und 13 weiteren Autor:innen. Beteiligte Einrichtung: Adelphi Values Patient-Centered Outcomes, Bollington, UK. brad.mason@omc.com. Hauptthemen laut MEDLINE: Non-Muscle Invasive Bladder Neoplasms, Patient Preference, BCG Vaccine, Urinary Bladder Neoplasms. Die Arbeit nennt 56 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Pfizer.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Bacillus Calmette-Guerin (BCG) following transurethral resection of bladder tumor (TURBT) is the current standard of care (SOC) for high-risk non-muscle invasive bladder cancer (HR-NMIBC). Several emerging therapies, such as immune checkpoint inhibitor (ICI) therapies in combination with BCG will provide new treatment options for patients. Patient preference studies can provide quantitative evidence of the trade-offs patients are willing to make among attributes of current and emerging treatments. Qualitative research is critical to developing preference elicitation instruments that capture decision-relevant treatment attributes. This study aimed to elicit information about HR-NMIBC patients' treatment priorities and evaluate a preliminary list of attributes and levels to be used in a patient preference survey. METHODS: A targeted literature review produced a preliminary list of 11 attributes. Qualitative, semi-structured, multi-method telephone interviews with 12 patients with HR-NMIBC in the USA were used to explore treatment decision drivers and assess comprehension and relevance of the attributes and levels. Patients with HR-NMIBC were recruited via patient advocacy groups. A combination of concept elicitation, cognitive debriefing, and rating and ranking exercises were used to assess patients' priorities and perspectives regarding decision-relevant treatment attributes. RESULTS: Efficacy (event-free survival) was the most important attribute to all patients. The risk of serious/life-threatening events was also very important to patients. The risk of experiencing bladder problems and the choice between different administration procedures (route, frequency) were also important in the context of patients' treatment choices. The preliminary list of attributes and levels was subsequently refined to reflect patient priorities and incorporate feedback from expert advisors. CONCLUSIONS: This is the first study, to our knowledge, that provides qualitative evidence regarding patients' preference for potential future treatment options for HR-NMIBC. Findings will inform the final selection and framing of attributes and levels to be included in an upcoming benefit-risk preference study. Future research is warranted to quantify any trade-offs that patients with HR-NMIBC are willing to make regarding administration, benefit, and risk attributes.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Non-Muscle Invasive Bladder NeoplasmsPatient PreferenceBCG VaccineUrinary Bladder NeoplasmsHumansFemaleMaleAgedMiddle AgedQualitative ResearchTransurethral Resection of BladderDecision MakingAged, 80 and over

Substanzen

BCG Vaccine

Autor:innen und Institutionen

  • Adelphi Values Patient-Centered Outcomes, Bollington, UK. brad.mason@omc.com.
  • Pfizer Inc., Surrey, UK.
  • Adelphi Values Patient-Centered Outcomes, Bollington, UK.
  • Pfizer Inc., New York, NY, USA.
  • Adelphi Research, Bollington, UK.
  • Pfizer Pharma GmbH, Friedrichstrasse 110, 10117, Berlin, Germany.

Förderung

  • Pfizer

Zitieren

APA

Mason, B., Eccleston, A., Ayala-Nunes, L., Hauber, B., Gater, A., Coulter, J., Hallworth, P., Thompson, A., Bell, B., Chang, J., Brinkmann, J., Cappelleri, J. C., Chisolm, S., & Satkunasivam, R. (2026). Incorporating the Patient Voice into Attribute and Level Selection for a Preference Study: A Qualitative Study in Non-Muscle Invasive Bladder Cancer. The Patient - Patient-Centered Outcomes Research. https://doi.org/10.1007/s40271-026-00804-7

Vancouver

Mason B, Eccleston A, Ayala-Nunes L, Hauber B, Gater A, Coulter J, et al. Incorporating the Patient Voice into Attribute and Level Selection for a Preference Study: A Qualitative Study in Non-Muscle Invasive Bladder Cancer. The Patient - Patient-Centered Outcomes Research. 2026. doi:10.1007/s40271-026-00804-7

BibTeX
@article{Mason2026,
  author = {Mason, Brad and Eccleston, Anthony and Ayala-Nunes, Lara and Hauber, Brett and Gater, Adam and Coulter, Joshua and Hallworth, Pam and Thompson, Allison and Bell, Bethany and Chang, Jane and Brinkmann, Julia and Cappelleri, Joseph C and Chisolm, Stephanie and Satkunasivam, Raj},
  title = {Incorporating the Patient Voice into Attribute and Level Selection for a Preference Study: A Qualitative Study in Non-Muscle Invasive Bladder Cancer},
  journal = {The Patient - Patient-Centered Outcomes Research},
  year = {2026},
  doi = {10.1007/s40271-026-00804-7}
}
Kostenlos starten →